Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of Treatment Pattern in COPD Patients Using Health Insurance Claims Data: Focusing on Inhaled Medications

건강 보험 청구 자료를 이용한 COPD 환자에서 치료제 처방 변화 분석: 흡입제를 중심으로

  • Lim, Hana (School of pharmacy, Sungkyunkwan University) ;
  • Park, Mihai (School of pharmacy, Sungkyunkwan University)
  • 임하나 (성균관대학교 약학대학) ;
  • 박미혜 (성균관대학교 약학대학)
  • Received : 2021.10.27
  • Accepted : 2022.06.25
  • Published : 2022.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is not completely reversible and requires long-term management with appropriate treatment. This study aimed to analyze trends in treatment regimens and medication costs for COPD patients using a national claims database. Methods: We conducted this analysis using National Patient Sample data from the Health Insurance Review and Assessment Service covering the period from 2015 to 2018. We have constructed a dataset comprising COPD disease classification codes J43.x and J44.x (based on KCD-7 code, J43.0 was excluded) and compiled a list of drugs fitting current guidelines. To identify trends, we calculated frequency, ratio, and compound annual growth rate (CAGR) using the numbers of prescriptions and patients. Results: The number of COPD patients was 7,260 in 2018, slightly decreased from 2015. Most of these COPD patients were aged 60 or older and included a high proportion of males (72.2%; 2018). The number of patients prescribed inhaled medications increased gradually from 2015 to 2018 (9,227 (47.1%); 2015, 9,285 (51.5%); 2018), while the number of patients prescribed systemic beta-agonists and Xanthines has decreased since 2015 (CAGR -14.7; systemic beta-agonist, -5.8; Xanthines). The per capita cost of medication has increased by 0.4% (KRW 206,667; 2018, KRW 204,278; 2015) annually during the study period. Conclusion: This study showed that treatment with inhaled medications had continuously increased in accord with changing guidelines, but oral medications were still widely used. It is necessary to emphasize the importance of inhaled medications in treating COPD to reduce additional economic burden through appropriate medication use.

Keywords

References

  1. Park YB, Rhee CK, Yoon HK et al. Revised (2018) COPD clinical practice guideline of the Korean academy of tuberculosis and respiratory disease: A summary. Tuberc Respir Dis (Seoul) 2018;81(4):261-73. https://doi.org/10.4046/trd.2018.0029
  2. Denguezli M, Daldoul H, Harrabi I et al. Prevalence and characteristics of undiagnosed COPD in adults 40 years and older - reports from the Tunisian population-based burden of obstructive lung disease study. COPD 2020;17(5):515-22. https://doi.org/10.1080/15412555.2020.1804848
  3. 2020 Current Status and Issues of Chronic Diseases. Available from https://kdca.go.kr/gallery.es?mid=a20503020000&bid=0003&act=view&list_no=144928. Accessed July 3, 2022.
  4. An TJ, Yoon HK. Prevalence and socioeconomic burden of chronic obstructive pulmonary disease. J Korean Med Assoc 2018;61(9):533-8. https://doi.org/10.5124/jkma.2018.61.9.533
  5. Hwang YI, Park YB, Yoo KH et al. Recent trends in the prevalence of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul) 2017;80(3):226-9. https://doi.org/10.4046/trd.2017.80.3.226
  6. Lee JM, Lee JH, Kim JA, Rhee CK. Trend of cost and utilization of COPD medication in Korea. Int J Chron Obstruct Pulmon Dis 2016;12:27-33. https://doi.org/10.2147/COPD.S121687
  7. Kim JE. Analysis of drug costs and trends in use of COPD. HIRA Policy Brief 2017;11(1):42-59.
  8. Kim SH, Cho BL, Shin DW, SS Hwang et al. The effect of asthma clinical guideline for adults on inhaled corticosteroids prescription trend: A quasi-experimental study. J Korean Med Sci 2015;30(8):1048-54. https://doi.org/10.3346/jkms.2015.30.8.1048
  9. Cho SH, Park HW, Rosenbergd DM. The current status of asthma in Korea. J Korean Med Sci 2006;21(2):181-7. https://doi.org/10.3346/jkms.2006.21.2.181
  10. Scanlon PD, Connett,JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161(2 Pt 1):381-90. https://doi.org/10.1164/ajrccm.161.2.9901044
  11. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta (2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;2012(9):CD006829.
  12. Calverley PMA, Anderson JA, Celli B, et al. TORCH investigators, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89. https://doi.org/10.1056/NEJMoa063070
  13. Wedzicha JA, Banerji D, Chapman KR et al. IndacaterolGlycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016;374(23):2222-34 https://doi.org/10.1056/NEJMoa1516385
  14. Lee GD, Doh SR, Lee JS et al. Trends and factors in health care utilization of patients with chronic obstructive pulmonary disease in Korea: A nationwide survey from 1990 through 2008. Tuberc Respir Dis 2011;70(4):307-14. https://doi.org/10.4046/trd.2011.70.4.307
  15. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US), 2014.
  16. Health Insurance Review & Assessment Service-Results of adequacy evaluation of chronic obstructive pulmonary disease in 2019 (6th). Available from https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=7209. Accessed July 3, 2022.
  17. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68(11): 1029-36. https://doi.org/10.1136/thoraxjnl-2012-202872
  18. Global Initiative for Chronic Obstructive Lung Disease-Global Strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease :2019 Report. Available from https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed July 3, 2022.
  19. Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: A systematic literature review. Int J Chron Obstruct Pulmon Dis 2020;15:417-38. https://doi.org/10.2147/COPD.S234823
  20. Cho KS. Current Status of Chronic Obstructive Pulmonary Disease (COPD) in the Republic of Korea. Public Health Weekly Report 2021;14(16):943-51.
  21. Global Strategy for Prevention, Diagnosis and Management of COPD: 2022 Report. Available from https://goldcopd.org/2022-gold-reports-2/. Accessed July 3, 2022.
  22. Price D, Freeman D, Cleland J, Kaplan A, Cerasoli F. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J 2011;20(1):15-22.
  23. Csikesz NG, Gartman EJ. New developments in the assessment of COPD: early diagnosis is key. Int J Chron Obstruct Pulmon Dis 2014;9:277-86.